Phase II Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents

Phase II Study of the Combination of Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents at Diagnosis or in Relapse

The purpose of this study is to determine whether the combination of Temozolomide and Cisplatinum is effective in the treatment of malignant glial tumours of children and adolescents

Inclusion Criteria:

• Age from 4th birthday and younger than 21st birthday
• Histologically documented malignant glial tumour (WHO classification grade III and IV) : astrocytoma, oligodendroglioma, oligoastrocytoma and mixed tumours
• Measurable and evaluable disease by the imaging criteria (MRI)
• Patient not previously treated by either of the two drugs

Exclusion Criteria:

• Malignant brain stem tumours are excluded